Table search / NewAmsterdam Pharma Company N.V. / "Bonus"

4 results

Newest first Best match first

2024 FY

Overall Payouts. Based on the assessment described above, the Compensation Committee recommended, and the Board of Directors determined, that the Company’s corporate performance exceeded the 2024 goals. The Compensation Committee determined an overall 2024 performance level, as determined with reference to both corporate performance and individual performance. The amounts of the annual bonus awards for 2024 were determined as follows:

NEO	Base Salary ($)		Target Annual Bonus %			Target Incentive Amount ($)		Overall Performance %			Payout ($)
Michael Davidson, M.D.		621,300		50	%		310,650		160	%		497,040
Ian Somaiya		468,000		45	%		210,600		175	%		368,550
John Kastelein, M.D., Ph.D. FESC (1)		486,046		40	%		186,946		175	%		327,031
Juliette Audet (2)(3)		424,480		40	%		169,792		150	%		188,406
Douglas Kling		500,000		40	%		200,000		200	%		399,974

26 Feb 25

8:00am

10-K

2024 FY

NAMS NewAmsterdam Pharma Company N.V.

Annual report

The following table sets forth information required under SEC rules concerning the compensation paid to our NEOs in respect of fiscal years ended December 31, 2024 and 2023.

Name and Principal Position	Year	Salary(1) ($)		Bonus ($)		Option Awards (2) ($)		Non-Equity Incentive Plan Compensation (3) ($)		All Other Compensation (4) ($)		Total ($)
Michael Davidson, M.D.	2024		621,300				5,347,060		497,040		3,897		6,469,297
Chief Executive Officer	2023		569,000		313,000		4,923,558						5,805,558
Ian Somaiya	2024		468,000				411,337		368,550		4,688		1,252,575
Chief Financial Officer	2023		90,576		40,000		3,422,493						3,553,069
John Kastelein, M.D., Ph.D. FESC	2024		486,046				2,570,852		327,031				3,383,929
Chief Scientific Officer	2023		459,346		218,412		2,300,813						2,978,571
Juliette Audet (5)	2024		322,254				2,602,746		188,406		25,068		3,138,474
Chief Business Officer	2023
Douglas Kling	2024		499,968				1,664,729		399,974		13,800		2,578,471
Chief Operating Officer	2023

26 Feb 25

8:00am

DEF 14A

NAMS NewAmsterdam Pharma Company N.V.

9 May 24

Definitive proxy

4:15pm

The following table sets forth information regarding compensation awarded to or earned by our named executive officers.


Name and Principal Position	Year	Salary ($)			Bonus ($)		Option Awards ($) (1)		Total ($)
Michael Davidson, M.D.	2023		569,000			313,000		4,923,558		5,832,558
Chief Executive Officer (2)
John Kastelein, M.D., Ph.D. FESC	2023		459,346	(3)		218,412		2,300,813		2,978,571
Chief Scientific Officer (4)
Ian Somaiya	2023		90,576			40,000		3,422,493		3,553,069
Chief Financial Officer (5)

10-K

2023 FY

NAMS NewAmsterdam Pharma Company N.V.

28 Feb 24

Annual report

8:00am

The following table sets forth information regarding compensation awarded to or earned by our named executive officers.

Name and Principal Position	Year	Salary ($)	Bonus ($)	Option Awards ($) (1)	Total ($)
Michael Davidson, M.D.	2023	569,000	313,000	4,923,558	5,832,558
Chief Executive Officer (2)
John Kastelein, M.D., Ph.D. FESC	2023	459,346 (3)	218,412	2,300,813	2,978,571
Chief Scientific Officer (4)
Ian Somaiya	2023	90,576	40,000	3,422,493	3,553,069
Chief Financial Officer (5)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.

Table search / NewAmsterdam Pharma Company N.V. / "Bonus"

4 results

Top filers

Top filing types

Recent filing years